# GLP-1 Receptor Agonists (Semaglutide)

**Category:** pharmaceutical
**Evidence Grade:** A
**Risk Profile:** medium

## Description
GLP-1 receptor agonist (Ozempic/Wegovy) originally for diabetes/obesity showing remarkable multi-organ benefits. Beyond weight loss, reduces cardiovascular events, kidney disease progression, and shows anti-inflammatory and neuroprotective effects. Being studied for Alzheimer prevention.

## Mechanisms of Action
- GLP-1 receptor agonism
- Appetite suppression (hypothalamic)
- Insulin secretion enhancement
- Systemic anti-inflammatory effects

## Dosage
- **Standard:** 0.25-2.4mg weekly (subcutaneous injection)
- **Range:** 0.25-2.4mg/week
- **Notes:** Prescription. Titrate slowly over 16+ weeks to minimize GI side effects. Weekly injection. Wegovy (obesity dose up to 2.4mg) vs Ozempic (diabetes dose up to 2mg).

## Key Findings
- SELECT trial: 20% reduction in major cardiovascular events in non-diabetic obese
- FLOW trial: 24% reduction in kidney disease progression
- Multiple ongoing trials for Alzheimer disease and NASH/liver disease

## Interactions
- Insulin (hypoglycemia risk)
- Oral contraceptives (delayed absorption)
- Other diabetes medications

## Side Effects
- Nausea (common, usually transient)
- Vomiting
- Diarrhea
- Pancreatitis (rare)
- Muscle loss (requires resistance training)

## Contraindications
- Personal/family history of medullary thyroid carcinoma
- MEN2 syndrome
- Pancreatitis history
- Gastroparesis

## Sources


## Suppliers


---
*Last updated: 2026-02-04T14:50:14.819Z*
